Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropharmacology ; 95: 1-11, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25747604

ABSTRACT

This study was designed to evaluate the neuroprotective effect of l-serine and the underlying mechanisms in mice after traumatic brain injury (TBI) induced using a weight drop model. The mice were intraperitoneally injected with l-serine 3 h after TBI and then injected twice each day for 7 days or until the end of the experiment. The neurological severity score, brain water content, lesion volume, and neurone loss were determined. The levels of TNF-α, IL-1ß, IL-6, and IL-10 and the number of GFAP- and Iba-1-positive cells and activated caspase-3-positive neurones in the brain tissue ipsilateral to TBI were also measured. Simultaneously, the influences of l-serine on these variables were observed. In addition, the expression of glycine receptors and l-serine-induced currents were measured. We found l-serine treatment: 1) decreased the neurological deficit score, brain water content, lesion volume, and neurone loss; 2) inhibited activated caspase-3; and 3) reduced the levels of TNF-α, IL-1ß and IL-6 and the number of GFAP- and Iba-1-positive cells. The effects of l-serine were antagonised by the administration of strychnine, an antagonist of glycine receptors. In addition, we found that glycine receptors were expressed mainly in the cortical neurones but less in the astrocytes or microglial cells, and l-serine activated these receptors and induced strychnine-sensitive currents in these neurones. In conclusion, l-serine induces the activation of glycine receptors, which alleviates neuronal excitotoxicity, a secondary brain injury process, thereby reduces the activation of astrocytes and microglial cells and secretion of proinflammatory cytokines and inhibits neuronal apoptosis. Thus, l-serine treatment leads to neuroprotection of brain tissue through reducing inflammatory responses and improves recovery of the neurological functions in mice after traumatic brain injury.


Subject(s)
Brain Injuries/drug therapy , Brain/drug effects , Neuroprotective Agents/pharmacology , Serine/pharmacology , Animals , Apoptosis/drug effects , Apoptosis/physiology , Astrocytes/drug effects , Astrocytes/pathology , Astrocytes/physiology , Brain/pathology , Brain/physiopathology , Brain Edema/drug therapy , Brain Edema/pathology , Brain Edema/physiopathology , Brain Injuries/pathology , Brain Injuries/physiopathology , Cytokines/metabolism , Disease Models, Animal , Glycine Agents/pharmacology , Mice, Inbred ICR , Microglia/drug effects , Microglia/pathology , Microglia/physiology , Neuroimmunomodulation/drug effects , Neuroimmunomodulation/physiology , Neurons/drug effects , Neurons/pathology , Neurons/physiology , Neuroprotection/drug effects , Neuroprotection/physiology , Random Allocation , Receptors, Glycine/antagonists & inhibitors , Receptors, Glycine/metabolism , Strychnine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...